Cardiac testing to manage cardiovascular risk in cancer patients

Seminars in Oncology

Volumn 40, Issue 2, 2013, Pages 147-155

  Davis, Margot ^a   Witteles, Ronald M ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTHRACYCLINE; DOXORUBICIN; NATRIURETIC FACTOR; TRASTUZUMAB;

ANGIOGENESIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER THERAPY; CARDIOTOXICITY; CARDIOVASCULAR RISK; CONGESTIVE HEART FAILURE; CORONARY ARTERY SPASM; DIABETES MELLITUS; ECHOCARDIOGRAPHY; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HUMAN; HYPERTENSION; PRIORITY JOURNAL;

ANGIOGENESIS INHIBITORS; ANTHRACYCLINES; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CORONARY VASOSPASM; DISEASE MANAGEMENT; HEART FAILURE; HUMANS; HYPERTENSION; NEOPLASMS; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84875693714     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2013.01.003     Document Type: Article

References (85)

1. D.L. Hoyert, J. Xu Deaths: preliminary data for 2011 Natl Vital Stat Rep 61 2012 1 64
2. S.M. Swain, F.S. Whaley, M.S. Ewer Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials Cancer 97 2003 2869 2879 (Pubitemid 36605157)
3. D.L. Hershman, R.B. McBride, A. Eisenberger, W.Y. Tsai, V.R. Grann, J.S. Jacobson Doxorubicin, cardiac risk factors, and cardiac toxicity in elderly patients with diffuse B-cell non-Hodgkin's lymphoma J Clin Oncol 26 2008 3159 3165
4. L.J. Steinherz, P.G. Steinherz, C.T. Tan, G. Heller, M.L. Murphy Cardiac toxicity 4 to 20 years after completing anthracycline therapy JAMA 266 1991 1672 1677
5. D.J. Slamon, B. Leyland-Jones, S. Shak Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2 N Engl J Med 344 2001 783 792 (Pubitemid 32222155)
6. B. Mackay, M.S. Ewer, C.H. Carrasco, R.S. Benjamin Assessment of anthracycline cardiomyopathy by endomyocardial biopsy Ultrastruct Pathol 18 1994 203 211 (Pubitemid 24131629)
7. M.S. Ewer, M.K. Ali, B. Mackay A comparison of cardiac biopsy grades and ejection fraction estimations in patients receiving adriamycin J Clin Oncol 2 1984 112 117 (Pubitemid 14152453)
8. R.G. Schwartz, W.B. McKenzie, J. Alexander Congestive heart failure and left ventricular dysfunction complicating doxorubicin therapy Seven-year experience using serial radionuclide angiocardiography Am J Med 82 1987 1109 1118
9. F. Corapcioglu, N. Sarper, F. Berk, T. Sahin, E. Zengin, H. Demir Evaluation of anthracycline-induced early left ventricular dysfunction in children with cancer: a comparative study with echocardiography and multigated radionuclide angiography Pediatr Hematol Oncol 23 2006 71 80 (Pubitemid 41769977)
10. J. Walker, N. Bhullar, N. Fallah-Rad Role of three-dimensional echocardiography in breast cancer: comparison with two-dimensional echocardiography, multiple-gated acquisition scans, and cardiac magnetic resonance imaging J Clin Oncol 28 2010 3429 3436
11. I. Klem, D.J. Shah, R.D. White Prognostic value of routine cardiac magnetic resonance assessment of left ventricular ejection fraction and myocardial damage: an international, multicenter study Circ Cardiovasc Imaging 4 2011 610 619
12. S. Petri, V. Esko, J. Esa A prospective comparison of cardiac magnetic resonance imaging and radionuclide ventriculography in the assessment of cardiac function in patients treated with anthracycline-based chemotherapy Nucl Med Commun 33 2012 51 59
13. L.J. Steinherz, T. Graham, R. Hurwitz Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of the Cardiology Committee of the Childrens Cancer Study Group Pediatrics 89 1992 942 949
14. R.M. Witteles, M.B. Fowler, M.L. Telli Chemotherapy-associated cardiotoxicity: how often does it really occur and how can it be prevented? Heart Fail Clin 7 2011 333 344
15. F. Dodos, T. Halbsguth, E. Erdmann, U.C. Hoppe Usefulness of myocardial performance index and biochemical markers for early detection of anthracycline-induced cardiotoxicity in adults Clin Res Cardiol 97 2008 318 326 (Pubitemid 351725058)
16. D. Di Lisi, F. Bonura, F. Macaione Chemotherapy-induced cardiotoxicity: role of the tissue Doppler in the early diagnosis of left ventricular dysfunction Anticancer Drugs 22 2011 468 472
17. A.C. Nagy, Z. Cserep, E. Tolnay, T. Nagykalnai, T. Forster Early diagnosis of chemotherapy-induced cardiomyopathy: a prospective tissue Doppler imaging study Pathol Oncol Res 14 2008 69 77
18. R. Pudil, J.M. Horacek, A. Strasova, L. Jebavy, J. Vojacek Monitoring of the very early changes of left ventricular diastolic function in patients with acute leukemia treated with anthracyclines Exp Oncol 30 2008 160 162 (Pubitemid 351951396)
19. K. Oztarhan, S. Guler, B. Aktas, M. Arslan, Z. Salcioglu, G. Aydogan The value of echocardiography versus cardiac troponin I levels in the early detection of anthracycline cardiotoxicity in childhood acute leukemia: prospective evaluation of a 7-year-long clinical follow-up Pediatr Hematol Oncol 28 2011 380 394
20. S. Tassan-Mangina, D. Codorean, M. Metivier Tissue Doppler imaging and conventional echocardiography after anthracycline treatment in adults: early and late alterations of left ventricular function during a prospective study Eur J Echocardiogr 7 2006 141 146 (Pubitemid 43257199)
21. D.A. Morris, L.H. Boldt, H. Eichstadt, C. Ozcelik, W. Haverkamp Myocardial systolic and diastolic performance derived by 2-dimensional speckle tracking echocardiography in heart failure with normal left ventricular ejection fraction Circ Heart Fail 5 2012 610 620
22. S.K. Saha, A. Kiotsekoglou, R.S. Toole Value of two-dimensional speckle tracking and real time three-dimensional echocardiography for the identification of subclinical left ventricular dysfunction in patients referred for routine echocardiography Echocardiography 29 2012 588 597
23. R. Jurcut, H. Wildiers, J. Ganame Strain rate imaging detects early cardiac effects of pegylated liposomal doxorubicin as adjuvant therapy in elderly patients with breast cancer J Am Soc Echocardiogr 21 2008 1283 1289
24. J.T. Poterucha, S. Kutty, R.K. Lindquist, L. Li, B.W. Eidem Changes in left ventricular longitudinal strain with anthracycline chemotherapy in adolescents precede subsequent decreased left ventricular ejection fraction J Am Soc Echocardiogr 25 2012 733 740
25. L.P. Budge, M. Salerno The role of cardiac magnetic resonance in the evaluation of patients presenting with suspected or confirmed acute coronary syndrome Cardiol Res Pract 2011 2011 605785
26. C. Parsai, R. O'Hanlon, S.K. Prasad, R.H. Mohiaddin Diagnostic and prognostic value of cardiovascular magnetic resonance in non-ischaemic cardiomyopathies J Cardiovasc Magn Reson 14 2012 54
27. R. Wassmuth, S. Lentzsch, U. Erdbruegger Subclinical cardiotoxic effects of anthracyclines as assessed by magnetic resonance imaging - a pilot study Am Heart J 141 2001 1007 1013 (Pubitemid 32477014)
28. E.R. Levin, D.G. Gardner, W.K. Samson Natriuretic peptides N Engl J Med 339 1998 321 328 (Pubitemid 28366422)
29. T. Wallen, S. Landahl, T. Hedner, K. Nakao, Y. Saito Brain natriuretic peptide predicts mortality in the elderly Heart 77 1997 264 267 (Pubitemid 27122781)
30. M.R. Cowie, A.D. Struthers, D.A. Wood Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care Lancet 350 1997 1349 1353 (Pubitemid 28036901)
31. L.K. Morrison, A. Harrison, P. Krishnaswamy, R. Kazanegra, P. Clopton, A. Maisel Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea J Am Coll Cardiol 39 2002 202 209 (Pubitemid 34084622)
32. T. Suzuki, D. Hayashi, T. Yamazaki Elevated B-type natriuretic peptide levels after anthracycline administration Am Heart J 136 1998 362 363 (Pubitemid 28368863)
33. M.T. Sandri, M. Salvatici, D. Cardinale N-terminal pro-B-type natriuretic peptide after high-dose chemotherapy: a marker predictive of cardiac dysfunction? Clin Chem 51 2005 1405 1410 (Pubitemid 41060872)
34. Kittiwarawut A, Vorasettakarnkij Y, Tanasanvimon S, Manasnayakorn S, Sriuranpong V. Serum NT-proBNP in the early detection of doxorubicin-induced cardiac dysfunction. Asia Pac J Clin Oncol. Epub 2012 Aug 16. 10.1111/j.1743-7563.2012.01588.x.
35. S. Ekstein, A. Nir, A.J. Rein N-terminal-proB-type natriuretic peptide as a marker for acute anthracycline cardiotoxicity in children J Pediatr Hematol Oncol 29 2007 440 444 (Pubitemid 47026244)
36. A. Dolci, R. Dominici, D. Cardinale, M.T. Sandri, M. Panteghini Biochemical markers for prediction of chemotherapy-induced cardiotoxicity: systematic review of the literature and recommendations for use Am J Clin Pathol 130 2008 688 695
37. D. Cardinale, A. Colombo, M.T. Sandri Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition Circulation 114 2006 2474 2481 (Pubitemid 44901520)
38. R. Seshadri, C. Matthews, A. Dobrovic, D.J. Horsfall The significance of oncogene amplification in primary breast cancer Int J Cancer 43 1989 270 272 (Pubitemid 19062423)
39. E.H. Romond, E.A. Perez, J. Bryant Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer N Engl J Med 353 2005 1673 1684 (Pubitemid 41464706)
40. M.J. Piccart-Gebhart, M. Procter, B. Leyland-Jones Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer N Engl J Med 353 2005 1659 1672 (Pubitemid 41464705)
41. T.M. Suter, M. Procter, D.J. van Veldhuisen Trastuzumab-associated cardiac adverse effects in the Herceptin Adjuvant Trial J Clin Oncol 25 2007 3859 3865 (Pubitemid 47477261)
42. C.G. Tocchetti, G. Ragone, C. Coppola Detection, monitoring, and management of trastuzumab-induced left ventricular dysfunction: an actual challenge Eur J Heart Fail 14 2012 130 137
43. A.L. Jones, M. Barlow, P.J. Barrett-Lee Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring Br J Cancer 100 2009 684 692
44. L.J. Murray, S. Ramakrishnan, L. O'Toole, I.H. Manifold, O.P. Purohit, R.E. Coleman Adjuvant trastuzumab in routine clinical practice and the impact of cardiac monitoring guidelines on treatment delivery Breast 19 2010 339 344
45. J.R. Mackey, M. Clemons, M.A. Cote Cardiac management during adjuvant trastuzumab therapy: recommendations of the Canadian Trastuzumab Working Group Curr Oncol 15 2008 24 35
46. H. Sawaya, I.A. Sebag, J.C. Plana Early detection and prediction of cardiotoxicity in chemotherapy-treated patients Am J Cardiol 107 2011 1375 1380
47. D. Cardinale, A. Colombo, R. Torrisi Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation J Clin Oncol 28 2010 3910 3916
48. A.A. Onitilo, J.M. Engel, R.V. Stankowski, H. Liang, R.L. Berg, S.A. Doi High-sensitivity C-reactive protein (hs-CRP) as a biomarker for trastuzumab-induced cardiotoxicity in HER2-positive early-stage breast cancer: a pilot study Breast Cancer Res Treat 134 2012 291 298
49. J.L. Hare, J.K. Brown, R. Leano, C. Jenkins, N. Woodward, T.H. Marwick Use of myocardial deformation imaging to detect preclinical myocardial dysfunction before conventional measures in patients undergoing breast cancer treatment with trastuzumab Am Heart J 158 2009 294 301
50. N. Fallah-Rad, J.R. Walker, A. Wassef The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated with adjuvant trastuzumab therapy J Am Coll Cardiol 57 2011 2263 2270
51. N. Fallah-Rad, M. Lytwyn, T. Fang, I. Kirkpatrick, D.S. Jassal Delayed contrast enhancement cardiac magnetic resonance imaging in trastuzumab induced cardiomyopathy J Cardiovasc Magn Reson 10 2008 5
52. M. Schmidinger, J. Larkin, A. Ravaud Experience with sunitinib in the treatment of metastatic renal cell carcinoma Ther Adv Urol 4 2012 253 265
53. G.M. Blumenthal, P. Cortazar, J.J. Zhang FDA approval summary: sunitinib for the treatment of progressive well-differentiated locally advanced or metastatic pancreatic neuroendocrine tumors Oncologist 17 2012 1108 1113
54. Y.Y. Xiao, P. Zhan, D.M. Yuan Chemotherapy plus multitargeted antiangiogenic tyrosine kinase inhibitors or chemotherapy alone in advanced NSCLC: a meta-analysis of randomized controlled trials Eur J Clin Pharmacol 69 2013 151 159
55. R.M. Steingart, G.L. Bakris, H.X. Chen Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitors Am Heart J 163 2012 156 163
56. Y. Izumiya, I. Shiojima, K. Sato, D.B. Sawyer, W.S. Colucci, K. Walsh Vascular endothelial growth factor blockade promotes the transition from compensatory cardiac hypertrophy to failure in response to pressure overload Hypertension 47 2006 887 893 (Pubitemid 44297560)
57. C.J. Richards, Y. Je, F.A. Schutz Incidence and risk of congestive heart failure in patients with renal and nonrenal cell carcinoma treated with sunitinib J Clin Oncol 29 2011 3450 3456
58. T.K. Choueiri, E.L. Mayer, Y. Je Congestive heart failure risk in patients with breast cancer treated with bevacizumab J Clin Oncol 29 2011 632 638
59. M.L. Telli, R.M. Witteles, G.A. Fisher, S. Srinivas Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate Ann Oncol 19 2008 1613 1618
60. P.S. Hall, R. Witteles, S. Srinivas, L.C. Harshman Incidence and severity of cardiotoxicity in metastatic renal cell carcinoma (RCC) patients treated with targeted therapies [abstract] J Clin Oncol 30 2012 Abstract 4610
61. R.B. Cohen, S. Oudard Antiangiogenic therapy for advanced renal cell carcinoma: management of treatment-related toxicities Invest New Drugs 30 2012 2066 2079
62. T.F. Chu, M.A. Rupnick, R. Kerkela Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib Lancet 370 2007 2011 2019 (Pubitemid 350236338)
63. Brunello A, Basso U, Sacco C, et al. Safety and activity of sunitinib in elderly patients (>=70 years) with metastatic renal cell carcinoma: a multicenter study. Ann Oncol. Epub 2012 Oct 19.
64. B.I. Rini, B. Escudier, P. Tomczak Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial Lancet 378 2011 1931 1939
65. K. Eechoute, A.A. van der Veldt, S. Oosting Polymorphisms in endothelial nitric oxide synthase (eNOS) and vascular endothelial growth factor (VEGF) predict sunitinib-induced hypertension Clin Pharmacol Ther 92 2012 503 510
66. S. George, P. Reichardt, T. Lechner, S. Li, D.P. Cohen, G.D. Demetri Hypertension as a potential biomarker of efficacy in patients with gastrointestinal stromal tumor treated with sunitinib Ann Oncol 23 2012 3180 3187
67. M. Azizi, A. Chedid, S. Oudard Home blood-pressure monitoring in patients receiving sunitinib N Engl J Med 358 2008 95 97
68. A. Bamias, E. Manios, A. Karadimou The use of 24-h ambulatory blood pressure monitoring (ABPM) during the first cycle of sunitinib improves the diagnostic accuracy and management of hypertension in patients with advanced renal cancer Eur J Cancer 47 2011 1660 1668
69. A.V. Chobanian, G.L. Bakris, H.R. Black The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report JAMA 289 2003 2560 2572 (Pubitemid 37430158)
70. C. Lestuzzi, E. Viel, E. Picano, N. Meneguzzo Coronary vasospasm as a cause of effort-related myocardial ischemia during low-dose chronic continuous infusion of 5-fluorouracil Am J Med 111 2001 316 318 (Pubitemid 32885628)
71. K. Becker, J.F. Erckenbrecht, D. Haussinger, T. Frieling Cardiotoxicity of the antiproliferative compound fluorouracil Drugs 57 1999 475 484 (Pubitemid 29196916)
72. C. Porta, M. Moroni, S. Ferrari, G. Nastasi Endothelin-1 and 5-fluorouracil-induced cardiotoxicity Neoplasma 45 1998 81 82 (Pubitemid 28247448)
73. A. Thyss, M.H. Gaspard, R. Marsault, G. Milano, C. Frelin, M. Schneider Very high endothelin plasma levels in patients with 5-FU cardiotoxicity Ann Oncol 3 1992 88
74. M. Cwikiel, J. Eskilsson, M. Albertsson, L. Stavenow The influence of 5-fluorouracil and methotrexate on vascular endothelium An experimental study using endothelial cells in the culture Ann Oncol 7 1996 731 737 (Pubitemid 26323547)
75. H. Millart, L. Brabant, M. Lorenzato, D. Lamiable, O. Albert, H. Choisy The effects of 5-fluorouracil on contractility and oxygen uptake of the isolated perfused rat heart Anticancer Res 12 1992 571 576
76. L.K. Shoemaker, U. Arora, C.M. Rocha Lima 5-Fluorouracil-induced coronary vasospasm Cancer Control 11 2004 46 49 (Pubitemid 38595787)
77. R.J. Luwaert, O. Descamps, F. Majois, J.M. Chaudron, M. Beauduin Coronary artery spasm induced by 5-fluorouracil Eur Heart J 12 1991 468 470
78. N.R. Shah, A. Shah, A. Rather Ventricular fibrillation as a likely consequence of capecitabine-induced coronary vasospasm J Oncol Pharm Pract 18 2012 132 135
79. S.A. Jensen, J.B. Sorensen Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine Cancer Chemother Pharmacol 58 2006 487 493 (Pubitemid 43999797)
80. M. de Forni, M.C. Malet-Martino, P. Jaillais Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study J Clin Oncol 10 1992 1795 1801 (Pubitemid 23059959)
81. S. Rezkalla, R.A. Kloner, J. Ensley Continuous ambulatory ECG monitoring during fluorouracil therapy: a prospective study J Clin Oncol 7 1989 509 514 (Pubitemid 19098146)
82. E. Hrovatin, E. Viel, C. Lestuzzi Severe ventricular dysrhythmias and silent ischemia during infusion of the antimetabolite 5-fluorouracil and cis-platin J Cardiovasc Med (Hagerstown) 7 2006 637 640 (Pubitemid 44350500)
83. A. Farina, C. Malafronte, M.A. Valsecchi, F. Achilli Capecitabine-induced cardiotoxicity: when to suspect? How to manage? A case report J Cardiovasc Med (Hagerstown) 10 2009 722 726
84. A.P. Ambrosy, P.L. Kunz, G.A. Fisher, R.M. Witteles Capecitabine-induced chest pain relieved by diltiazem Am J Cardiol 110 2012 1623 1626
85. J. Cerny, A. Hassan, C. Smith, B. Piperdi Coronary vasospasm with myocardial stunning in a patient with colon cancer receiving adjuvant chemotherapy with FOLFOX regimen Clin Colorectal Cancer 8 2009 55 58